Amphastar Continues To Push Proprietary Portfolio With Focus On Baqsimi
The Company Expects Several Regulatory Milestones In 2025
Amphastar’s leadership has discussed its strategy and latest results as part of a fireside chat at this year’s Jefferies Healthcare Conference, restating its expectations of potential approvals of its GLP-1 candidate in 2025.
